JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World

Treatment decisions in psoriatic arthritis (PsA) often hinge on balancing disease control with long-term safety, especially when considering targeted therapies like Janus kinase (JAK) inhibitors. Regulatory warnings issued after the ORAL Surveillance trial prompted a cautious approach to these agents in clinical practice, with clinicians often reserving them for patients who fail tumor necrosis factor (TNF) inhibitors. A large 2025 meta-analysis by Solitano and colleagues, however, offers a more nuanced perspective of how these therapies compare in real-world practice.

Safety Signals in PsA Therapy

The analysis pooled data from 42 head-to-head comparative effectiveness studies involving more than 813,000 patients with immune-mediated inflammatory diseases, including PsA. The investigators evaluated key safety outcomes associated with JAK inhibitors compared with TNF antagonists, including serious infections, malignancy, cardiovascular events, and venous thromboembolism (VTE).

For clinicians managing PsA, the overall message is clear: major safety differences between these classes appear limited.

Subgroup findings offered several clinically relevant signals:

• Serious infections: Rates were similar between JAK inhibitors and TNF inhibitors.
• Malignancy: No consistent difference emerged, though PsA-specific sample sizes were relatively small.
• Major cardiovascular events: No meaningful difference was seen between treatment classes across inflammatory disease populations.
• Venous thromboembolism: A modestly higher relative risk with JAK inhibitors was observed overall, but absolute event rates remained low.

Within PsA cohorts, serious infection rates appeared comparable between the two therapies, aligning with the broader trends observed across inflammatory diseases.

Implications for Decision Making

Patients with psoriatic arthritis often differ from the high-risk populations that initially triggered concerns about JAK inhibitor safety. Compared with the high-risk rheumatoid arthritis population enrolled in the ORAL Surveillance trial, patients with psoriatic arthritis in routine practice are often younger and may have different comorbidity profiles.

Real-world comparative studies therefore provide valuable context when considering treatment sequencing in PsA. The current evidence suggests that the safety gap between JAK inhibitors and TNF inhibitors may be narrower than originally feared, particularly when patients are appropriately selected and monitored.

Patient-specific risk factors—including a history of thrombosis, smoking, obesity, and underlying cardiovascular disease—should help guide treatment decisions. At the same time, achieving effective disease control is critical as persistent inflammation can contribute to both infection risk and long-term cardiovascular complications. Ultimately, therapy selection should be individualized, taking into account prior biologic exposure, patient preference for oral versus injectable treatments, and the patient’s specific disease phenotype.

As longer-term and PsA-specific safety data continue to accumulate, JAK inhibitors may increasingly be viewed not simply as fallback options but as strategic components of individualized PsA management. For many PsA patients, the question may not be whether JAK inhibitors are safe enough—but which patients are the right candidates for them.

Reference:

Solitano V, Ahuja D, Lee HH, et al. Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(9):e2531204. doi:10.1001/jamanetworkopen.2025.31204.